Massachusetts Institute of Technology

The Broad Institute, Inc.

Thomas Nieland

Benito Munoz

Monty Krieger

Sivaraman Dandapani

Partha Pratim Nag

Miao Yu

Chris Dockendorff

Willmen Youngsaye

Patrick Faloon

Timothy A Lewis

Andrew Germain

This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.

Thiazole-based inhibitors of scavenger receptor BI

This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can be used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections. The compounds have the formula: wherein Rand Rare independently H, halogen, cyano, haloalkyl, haloalkyloxy or OMe; or Rand Rtogether are &#x2014;O&#x2014;CH&#x2014; or &#x2014;O&#x2014;CF&#x2014;O&#x2014;; Ris H, halogen, cyano, haloalkyl or haloalkyloxy; Ris Calkyl, Ccycloalkyl, Ccycloalkylmethyl or Ccycloheteroalkyl, wherein the heteroatom is N or O; Ris H or CH; Ris Calkyl or Ccycloalkyl; and A, B, D and E are each, independently, CH, N, O or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, O or S. 

Heterocycle-bisamide inhibitors of scavenger receptor BI

Growing community of inventors

Somerville, MA, United States of America

Thomas Nieland